Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Amneal Pharmaceuticals stock price, quote, forecast and news

AMRX
US03168L1052
A2JLMD

Price

8.62
Today +/-
+0.14
Today %
+1.76 %
P

Amneal Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Amneal Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Amneal Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Amneal Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Amneal Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Amneal Pharmaceuticals Stock Price History

DateAmneal Pharmaceuticals Price
9/13/20248.62 undefined
9/12/20248.47 undefined
9/11/20248.36 undefined
9/10/20248.38 undefined
9/9/20248.46 undefined
9/6/20248.39 undefined
9/5/20248.45 undefined
9/4/20248.49 undefined
9/3/20248.49 undefined
8/30/20248.66 undefined
8/29/20248.67 undefined
8/28/20248.61 undefined
8/27/20248.48 undefined
8/26/20248.47 undefined
8/23/20248.38 undefined
8/22/20248.05 undefined
8/21/20248.14 undefined
8/20/20248.10 undefined
8/19/20248.15 undefined

Amneal Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Amneal Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amneal Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amneal Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Amneal Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Amneal Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Amneal Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amneal Pharmaceuticals’s growth potential.

Amneal Pharmaceuticals Revenue, EBIT and net profit per share

DateAmneal Pharmaceuticals RevenueAmneal Pharmaceuticals EBITAmneal Pharmaceuticals Net Income
2028e2.83 B undefined0 undefined289.64 M undefined
2027e2.74 B undefined420.44 M undefined261.3 M undefined
2026e2.99 B undefined553.96 M undefined243.46 M undefined
2025e2.71 B undefined528.39 M undefined203.06 M undefined
2024e2.61 B undefined515.55 M undefined182.6 M undefined
20232.39 B undefined274.85 M undefined-83.99 M undefined
20222.21 B undefined199.3 M undefined-129.99 M undefined
20212.09 B undefined216.4 M undefined10.62 M undefined
20201.99 B undefined145.7 M undefined91.1 M undefined
20191.63 B undefined-12.7 M undefined-361.9 M undefined
20181.66 B undefined284.5 M undefined-20.9 M undefined
2017775.8 M undefined-153.3 M undefined-469.3 M undefined
2016824.4 M undefined-433.4 M undefined-472 M undefined
2015860.5 M undefined87.9 M undefined39 M undefined
2014596 M undefined97 M undefined57.4 M undefined
2013511.5 M undefined24.1 M undefined101.3 M undefined
2012581.7 M undefined97.2 M undefined55.9 M undefined
2011512.9 M undefined107.1 M undefined65.5 M undefined
2010879.5 M undefined399.7 M undefined250.4 M undefined
2009358.4 M undefined85.1 M undefined50.1 M undefined
2008210.1 M undefined10.4 M undefined16 M undefined
2007273.8 M undefined86.5 M undefined125.4 M undefined
2006135.2 M undefined1 M undefined-12 M undefined
2005112.4 M undefined2.1 M undefined-5.8 M undefined
200358.8 M undefined-13.5 M undefined-14.2 M undefined

Amneal Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199719981999200020012002200320052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
0000.010.010.020.060.110.140.270.210.360.880.510.580.510.60.860.820.781.661.631.992.092.212.392.612.712.992.742.83
---900.00-40.00300.00141.6793.1020.54102.22-23.0870.48145.53-41.7513.48-12.0516.6344.30-4.19-5.95114.58-2.2222.515.075.698.189.113.6810.42-8.263.03
-----50.0025.0025.8648.2146.6760.8156.1952.5161.3250.3948.5441.4952.8541.74-18.3318.4543.6029.4633.2837.7935.9435.77-----
0000-36155463166118188539258282212315359-15114372547966379179585600000
-3-5-7-21-25-20-132186108539910797249787-433-153284-121452161992745155285534200
---700.00-210.00-416.67-83.33-22.411.790.7431.504.7623.7445.3920.9016.704.7016.2810.12-52.55-19.7417.08-0.747.2810.329.0011.4519.7219.5018.5015.32-
-3-5-8-25-25-20-14-5-12125165025065551015739-472-469-20-3619110-129-83182203243261289
-66.6760.00212.50--20.00-30.00-64.29140.00-1,141.67-87.20212.50400.00-74.00-15.3883.64-43.56-31.58-1,310.26-0.64-95.741,705.00-125.21-89.01-1,390.00-35.66-319.2811.5419.707.4110.73
7.17.2827.541.647.451.3595961.260.861.165.667.368.468.770.57271.171.9127.3132.1148.9151.82150.94176.1400000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Amneal Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Amneal Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1998199920002001200220032005200620072008200920102011201220132014201520162017201820192020202120222023
                                                 
0.47.419.235.510.215.556.129.8143.512090.4348.4346.4298.9413.1414.9340.4180.1181.8213.4151.2341.4247.7925.9891.54
041.63.56.59.930.561.951.543.3185.982.1153.892.2113146.5324.5257.4240.8481.5604.4638.9662.58741.79613.73
00000000000000000061.247.431.535.365.1655.1231.93
022.93.510.528.533.334.127.632.349.144.554.289.870.180.6125.6175.2158.5457.2381.1490.6489.39530.74581.38
00.30.41.511.4954.847.940.848.645.745.664.663.533.731.718.453.487.14245.355.1958.259.28
00.010.020.040.030.060.130.180.270.240.370.520.60.550.660.680.820.630.71.291.211.551.521.411.38
38.19.724.337.138.155.369.481.295.6101.7106.3118.2180.8188.2188.2214.2233.4124.8544.1620.2605.2639589.36550.14
0000000000000000000000085.590
000000000000000000000032.0655.120
00-0-0.010000000000.050.030.030.60.620.261.661.381.31.171.10.89
034.734.734.727.627.627.627.627.627.627.627.627.627.627.627.6210.2207.3207.3426.2419.5522.8593.02598.85598.63
00.70.70.610.811.348.666.2137.2154.7157.538.845.962.191.7161.174.1130.761.1440.833.321.920.61103.2255.52
00.050.040.050.080.080.130.160.250.280.290.170.190.320.340.41.11.190.663.072.462.452.452.532.09
00.060.070.10.10.130.260.340.520.510.660.690.790.8611.081.921.821.354.353.674.013.973.943.47
                                                 
8.222.228.6888.10.60.60.60.60.60.60.70.70.70.70.70.70.73333.013.043.07
4.751.776.7123131.1170.1182.5183.8196211.1223.2255.4286314.7336.6364.1504.1535.1559.6530.4607628.4658.35691.63539.24
-11.3-20.2-45.2-70.3-90.3-104.5-174.2-186.2-60.3-49.20.8251.2316.7372.6473.9531.2570.298.2-372.4-20.9-377.9-286.8-276.2-406.18-490.18
0-1.5-1.1-0.7-0.20000-1-0.52.81.75.21.1-6-10.5-7.91.4-7.8-0.1-41.3-24.839.94-32.35
0000000000000000000000000
00.050.060.060.050.070.01-00.140.160.220.510.610.690.810.891.060.630.190.50.230.30.360.30.02
0.92.42.347.522.812.614.616.912.823.318.82341.326.83256.35981.1114.8102151.1189.08165.98143.57
0.12.71.53.610.910.948.330.235.841.4115.886.9109.896.1101.9125.8269.6244.7248.1399.6410.2464.3404.06383.05403.12
0.2000001252.238.44164.820.724.27.825.20.90.807.217.714.713.150.38110.3284.31
01.92.4047.60000000000000000060179
00.50.10.20.91.10.11.869.214.4000000017.717.821.723.548.433.7233.4536.59
1.27.56.37.823.342.47398.8160.3109.6203.9126.4157145.2153.9158.7326.7321.4354.2553.8550.4676.9677.24752.8846.59
0000.010.010.010.080.090.020.010000000.420.810.772.672.672.832.782.692.49
0000000.500000000072.803.21.200000
0.50.50.42323.57.997.6159.5201.4239.1234.758.834.127.632.832.63664.237.1231.794.2138.2100.2145.1678.65
0000.030.030.020.180.250.220.250.230.060.030.030.030.030.530.880.812.92.772.972.882.842.56
00.010.010.040.060.060.250.350.380.350.440.190.190.170.190.190.861.21.163.463.323.653.563.593.41
00.060.070.10.10.130.260.350.520.520.660.70.80.8711.081.921.831.353.963.553.953.923.893.43
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Amneal Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Amneal Pharmaceuticals's financial health and stability.

Assets

Amneal Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Amneal Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Amneal Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Amneal Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19971998199920002001200220032005200620072008200920102011201220132014201520162017201820192020202120222023
-3-5-8-25-25-20-14-5-12125165025065551015739-472-469-201-6036820-254-48
000652357891112157736346888109137207235233240229
000000000163-10427-23-21-11-29-12774-93710000
000-101-54-2418-1-9782-8637-11-76-19-44-117-120-61-133-59-47
001400-31723-493638-1384-41442933639380484168157150171238
00000012343000000151828131158130121142192
00000000014801292455347243232-3510100-15-12-2
-2-3-6-16-17-15-1921-511964-8249610514932928384250137924165345
-1-10-3-16-15-4-14-21-18-25-14-16-30-171-44-42-31-52-26-97-97-66-52-90-69
2-10-11-295-435-43-9832-21-213-15-85-115-16-467-627-9-396-19-317-194-174-69
301-7-1220050-22-7958-7-1971585-7126-436-57417-29977-251-141-830
00000000000000000000000000
0000363-2700-65-1200000453395-70541-29143-79-3822
32123125725000051714128119991310000
32123150528-29010-65-7232117914500382-73287-45131-138-106-212
000022-90-20100066403-51-21-5-74-18-11-59-69-235
00000000000000000000-18300000
2-2743-4526-493131-376012374230125-1601140-65194-90-22163
-4.1-5.1-7.2-19.6-34.5-30.3-23.66.4-27.3100.238.7-22.6233.5-24.4-65.9105.1-10.161.53157.4153.1-95.7312.8189.18-25.5276.39
00000000000000000000000000

Amneal Pharmaceuticals stock margins

The Amneal Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amneal Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amneal Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Amneal Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Amneal Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Amneal Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Amneal Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amneal Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amneal Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amneal Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Amneal Pharmaceuticals Margin History

Amneal Pharmaceuticals Gross marginAmneal Pharmaceuticals Profit marginAmneal Pharmaceuticals EBIT marginAmneal Pharmaceuticals Profit margin
2028e35.79 %0 %10.25 %
2027e35.79 %15.33 %9.53 %
2026e35.79 %18.53 %8.15 %
2025e35.79 %19.52 %7.5 %
2024e35.79 %19.75 %6.99 %
202335.79 %11.48 %-3.51 %
202235.97 %9.01 %-5.88 %
202137.81 %10.34 %0.51 %
202033.27 %7.31 %4.57 %
201929.46 %-0.78 %-22.25 %
201843.62 %17.11 %-1.26 %
201718.54 %-19.76 %-60.49 %
2016-18.33 %-52.57 %-57.25 %
201541.8 %10.21 %4.53 %
201452.95 %16.28 %9.63 %
201341.54 %4.71 %19.8 %
201248.58 %16.71 %9.61 %
201150.36 %20.88 %12.77 %
201061.32 %45.45 %28.47 %
200952.48 %23.74 %13.98 %
200856.21 %4.95 %7.62 %
200760.66 %31.59 %45.8 %
200646.6 %0.74 %-8.88 %
200548.04 %1.87 %-5.16 %
200325.51 %-22.96 %-24.15 %

Amneal Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Amneal Pharmaceuticals earnings per share therefore indicates how much revenue Amneal Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amneal Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amneal Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amneal Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amneal Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amneal Pharmaceuticals Revenue, EBIT and net profit per share

DateAmneal Pharmaceuticals Sales per ShareAmneal Pharmaceuticals EBIT per shareAmneal Pharmaceuticals Earnings per Share
2028e9.16 undefined0 undefined0.94 undefined
2027e8.88 undefined0 undefined0.85 undefined
2026e9.68 undefined0 undefined0.79 undefined
2025e8.77 undefined0 undefined0.66 undefined
2024e8.46 undefined0 undefined0.59 undefined
202313.59 undefined1.56 undefined-0.48 undefined
202214.66 undefined1.32 undefined-0.86 undefined
202113.79 undefined1.43 undefined0.07 undefined
202013.38 undefined0.98 undefined0.61 undefined
201912.31 undefined-0.1 undefined-2.74 undefined
201813.06 undefined2.23 undefined-0.16 undefined
201710.79 undefined-2.13 undefined-6.53 undefined
201611.59 undefined-6.1 undefined-6.64 undefined
201511.95 undefined1.22 undefined0.54 undefined
20148.45 undefined1.38 undefined0.81 undefined
20137.45 undefined0.35 undefined1.47 undefined
20128.5 undefined1.42 undefined0.82 undefined
20117.62 undefined1.59 undefined0.97 undefined
201013.41 undefined6.09 undefined3.82 undefined
20095.87 undefined1.39 undefined0.82 undefined
20083.46 undefined0.17 undefined0.26 undefined
20074.47 undefined1.41 undefined2.05 undefined
20062.29 undefined0.02 undefined-0.2 undefined
20051.91 undefined0.04 undefined-0.1 undefined
20031.15 undefined-0.26 undefined-0.28 undefined

Amneal Pharmaceuticals business model

Amneal Pharmaceuticals Inc is a leading pharmaceutical company headquartered in Bridgewater, New Jersey, USA. It was founded in 2002 by Chirag Patel and Chintu Patel, both of whom were involved in the generic pharmaceutical industry. Amneal specializes in the development, manufacturing, and marketing of high-quality, cost-effective generic and specialty pharmaceuticals for a variety of therapeutic areas. The company's mission is to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal operates globally in over 50 countries, with global facilities in India, Ireland, and other countries. The company strives to provide innovation, exceptional service, and reliability to customers and patients worldwide. Over the years, the company has rapidly grown to become a major player in the global pharmaceutical market. It offers a wide range of products, including both generic and specialty pharmaceuticals in numerous therapy areas. These areas include oncology, central nervous system (CNS), gastroenterology, dermatology, immunology, pain management, and many others. Amneal places a strong emphasis on clinical research and development to create innovative medications and therapies that meet the needs of today's patients. The company has multiple research and development centers worldwide, including in Israel, India, and the USA, where it collaborates closely with industry partners to develop new products. Another hallmark of Amneal is its ability to provide high-quality generic pharmaceuticals that meet the needs of customers in different countries and regions. The company manufactures its products to the highest standards and has a strict quality assurance system to ensure that patients can rely on receiving medications of the highest quality and efficacy. Amneal's product line is extensive, encompassing a variety of drugs ranging from simple over-the-counter (OTC) preparations to complex steroids and oncology therapeutics. Some of its key products include Tamoxifen Citrate, Lamotrigine, Methylphenidate Hydrochloride, Warfarin Sodium, Buprenorphine-Naloxone, and many others. Amneal Pharmaceuticals also forms partnerships with other companies to expand and diversify its business model. In 2018, Amneal merged with Impax Laboratories, Inc., a leading pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty products for various therapy areas. The merger brought together both companies, creating an entity with a broader product portfolio, a larger global reach, and stronger development and marketing expertise. In summary, Amneal Pharmaceuticals Inc is a leading pharmaceutical company focused on the development and marketing of generic and specialty pharmaceuticals for a variety of therapeutic areas. The company is on a mission to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal prioritizes clinical research and development to create innovative medications and therapies, and it has a strict quality assurance system. The company has a wide product range and collaborates closely with other companies to expand its business model and global reach. Amneal Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Amneal Pharmaceuticals SWOT Analysis

Strengths

Amneal Pharmaceuticals Inc possesses several strengths, which contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong product portfolio offering a diverse range of pharmaceutical products
  • Robust manufacturing capabilities and state-of-the-art facilities
  • Strong research and development capabilities, fostering innovation and new product development
  • Established global presence and a wide distribution network
  • Strong financial performance and a solid revenue base
  • Experienced and knowledgeable management team with a proven track record

Weaknesses

Despite its strengths, there are also some weaknesses that Amneal Pharmaceuticals Inc needs to address in order to maintain its competitive position:

  • Reliance on a limited number of key customers for a significant portion of its revenue
  • Dependency on third-party suppliers for raw materials and components
  • Significant competition in the pharmaceutical industry, leading to pricing pressures
  • Limited geographic diversification, with a majority of revenue generated from the US market
  • Investment required to keep up with rapidly evolving technological advancements

Opportunities

Amneal Pharmaceuticals Inc can capitalize on the following opportunities to further expand its business and enhance its market position:

  • Increasing demand for generic drugs as healthcare costs continue to rise
  • Growing prevalence of chronic diseases, creating a larger market for pharmaceutical products
  • Expanding into emerging markets with favorable regulatory environments
  • Strategic partnerships and collaborations for research and development of new therapies
  • Investing in advanced manufacturing technologies to improve efficiency and reduce costs

Threats

Amneal Pharmaceuticals Inc faces various threats that could potentially hinder its growth and profitability:

  • Intense competition from both generic and branded pharmaceutical companies
  • Risk of patent expirations, leading to increased competition and price erosion
  • Stringent regulatory requirements and compliance costs
  • Potential lawsuits and legal challenges related to intellectual property and product safety
  • Volatility in raw material prices and supply chain disruptions
  • Global economic downturns impacting consumer spending and healthcare budgets

Amneal Pharmaceuticals Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Amneal Pharmaceuticals Revenue by Segment

Segmente20232022202120202019
Distribution347.41 M USD260.56 M USD192.92 M USD161.67 M USD-
Central nervous system249.98 M USD---659.26 M USD
Central Nervous System-255.66 M USD277.2 M USD285.74 M USD-
Hormonal allergy----410.21 M USD
Oncology110.46 M USD64.29 M USD103.33 M USD61.11 M USD62.72 M USD
Cardiovascular System-118.18 M USD141.87 M USD114.23 M USD-
Government Label-98.23 M USD118.38 M USD104.05 M USD-
Dermatology70.87 M USD66.55 M USD55.47 M USD58.17 M USD60.19 M USD
Cardiovascular system139.94 M USD---117.07 M USD
Hormonal/Allergy-91.47 M USD68.4 M USD54.63 M USD-
Respiratory42.71 M USD41.09 M USD35.97 M USD37.39 M USD34.92 M USD
Gastroenterology67.52 M USD70.8 M USD78,000 USD1.6 M USD47.01 M USD
Other24.5 M USD19.57 M USD12.54 M USD9.47 M USD91.06 M USD
Antiviral39.91 M USD40.6 M USD-25.72 M USD27.49 M USD
Government label121.83 M USD----
Hormonal / allergy110.49 M USD----
Institutional38.02 M USD27.74 M USD25.18 M USD18.55 M USD-
Anti-Infective-23.19 M USD30.5 M USD40.38 M USD-
Other therapeutic classes29.99 M USD27 M USD---
Metabolic disease endocrine----56.68 M USD
Metabolic disease / endocrine45.9 M USD----
Metabolic Disease/Endocrine-41.13 M USD50,000 USD646,000 USD-
Anti infective----36.32 M USD
Anti-infective25.89 M USD----
License Agreement-8.02 M USD---
Antiviral (1)--4.83 M USD--
Royalties----2.86 M USD
License agreement-----
Aspirin; Dipyridamole ER Capsul-----
Diclofenac Sodium Gel-----
Epinephrine Auto-Injector family (generic Adrenaclick®)-----
Rytary® family-----
Yuvafem-Estradiol-----
Generics--1.37 B USD1.34 B USD-
Specialty390.46 M USD374.12 M USD378.32 M USD355.57 M USD-
Generics1.47 B USD1.43 B USD---
Generics Segment----1.31 B USD
AvKARE531.75 M USD406.11 M USD-293.75 M USD-
Av Kare--349.01 M USD--
Specialty Segment----317.53 M USD

Amneal Pharmaceuticals Revenue by Region

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Amneal Pharmaceuticals Revenue by Segment

DateInternationalInternational and otherUS
2023-2.17 M USD-
2022-1.47 M USD-
2021-1.3 M USD-
2020-2.33 M USD-
201920.6 M USD-1.6 B USD

Amneal Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Amneal Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Amneal Pharmaceuticals shares outstanding

The number of shares was Amneal Pharmaceuticals in 2023 — This indicates how many shares 176.136 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amneal Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amneal Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amneal Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amneal Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Amneal Pharmaceuticals.

Amneal Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230.13 0.19  (46.95 %)2023 Q3
6/30/20230.11 0.19  (75.76 %)2023 Q2
3/31/20230.1 0.12  (22.57 %)2023 Q1
12/31/20220.21 0.23  (7.73 %)2022 Q4
9/30/20220.18 0.14  (-22.39 %)2022 Q3
6/30/20220.2 0.19  (-4.14 %)2022 Q2
3/31/20220.13 0.12  (-9.02 %)2022 Q1
12/31/20210.2 0.18  (-11.24 %)2021 Q4
9/30/20210.21 0.21  (0.77 %)2021 Q3
6/30/20210.19 0.25  (33.4 %)2021 Q2
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Amneal Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

28/ 100

🌱 Environment

8

👫 Social

42

🏛️ Governance

34

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Amneal Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
6.97272 % Fosun International Ltd21,521,30106/30/2023
4.29670 % Patel (Gautam)13,261,751010/16/2023
4.21615 % The Vanguard Group, Inc.13,013,152-128,6296/30/2023
3.99442 % TPG Capital, L.P.12,328,76706/30/2023
2.34066 % BlackRock Institutional Trust Company, N.A.7,224,4331,020,9706/30/2023
1.70590 % Eversept Partners, LP5,265,25182,2056/30/2023
1.21430 % Neuberger Berman, LLC3,747,93965,3126/30/2023
0.87944 % Norges Bank Investment Management (NBIM)2,714,4002,714,40012/31/2022
0.84282 % Rubric Capital Management LP2,601,3792,601,3796/30/2023
0.72274 % State Street Global Advisors (US)2,230,737100,7686/30/2023
1
2
3
4
5
...
10

Amneal Pharmaceuticals Executives and Management Board

Mr. Chintu Patel51
Amneal Pharmaceuticals Co-Chief Executive Officer, Co-Founder, Director (since 2018)
Compensation 5.06 M
Mr. Chirag Patel56
Amneal Pharmaceuticals President, Co-Chief Executive Officer, Co-Founder, Director (since 2018)
Compensation 5.05 M
Mr. Anastasios Konidaris56
Amneal Pharmaceuticals Chief Financial Officer, Executive Vice President
Compensation 2.73 M
Mr. Andrew Boyer57
Amneal Pharmaceuticals Executive Vice President, Chief Commercial Officer - Generics
Compensation 2.68 M
Ms. Nikita Shah45
Amneal Pharmaceuticals Chief Human Resource Officer, Executive Vice President
Compensation 2.26 M
1
2
3
4

Most common questions regarding Amneal Pharmaceuticals

What values and corporate philosophy does Amneal Pharmaceuticals represent?

Amneal Pharmaceuticals Inc is committed to delivering quality generic pharmaceutical products. Their corporate philosophy revolves around providing affordable, accessible, and innovative healthcare solutions. With a focus on research and development, they strive to improve patient lives and enhance overall well-being. By offering a diverse portfolio of high-quality generic medications, Amneal Pharmaceuticals Inc aims to make healthcare more accessible and contribute to the overall welfare of society. They prioritize excellence, accountability, and integrity, all while aiming to deliver sustainable value to patients, healthcare providers, and other stakeholders.

In which countries and regions is Amneal Pharmaceuticals primarily present?

Amneal Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Amneal Pharmaceuticals achieved?

Amneal Pharmaceuticals Inc has achieved several significant milestones throughout its history. The company has successfully expanded its product portfolio, offering a wide range of generic pharmaceuticals, specialty drugs, and over-the-counter products. Additionally, Amneal Pharmaceuticals Inc has made strategic acquisitions and partnerships to strengthen its global presence and enhance its research and development capabilities. The company has also received multiple approvals from regulatory authorities for its Abbreviated New Drug Applications (ANDAs) and has launched various generic medications in the market. Overall, Amneal Pharmaceuticals Inc has demonstrated continuous growth and innovation, positioning itself as a leading player in the pharmaceutical industry.

What is the history and background of the company Amneal Pharmaceuticals?

Amneal Pharmaceuticals Inc is a prominent pharmaceutical company with a rich history and background. Founded in 2002, the company has grown rapidly to become a leading provider of high-quality generic and specialty pharmaceutical products. Amneal focuses on developing, manufacturing, and distributing a diverse range of innovative and affordable medications to improve patients' lives. With a strong commitment to quality, the company has established a robust portfolio of FDA-approved products and consistently achieves high safety and efficacy standards. Amneal Pharmaceuticals Inc has also expanded globally, operating in multiple countries to serve a wider patient population.

Who are the main competitors of Amneal Pharmaceuticals in the market?

The main competitors of Amneal Pharmaceuticals Inc in the market include major pharmaceutical companies such as Teva Pharmaceutical Industries Ltd, Mylan N.V, and Endo International plc.

In which industries is Amneal Pharmaceuticals primarily active?

Amneal Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Amneal Pharmaceuticals?

The business model of Amneal Pharmaceuticals Inc is focused on developing, manufacturing, and distributing high-quality generic and specialty pharmaceutical products. Amneal aims to provide affordable and accessible medications to patients worldwide, while adhering to stringent quality standards. The company operates through its robust supply chain, leveraging its extensive manufacturing capabilities and scientific expertise to produce a diverse portfolio of pharmaceutical products. Amneal Pharmaceuticals Inc is dedicated to continuously improving patient outcomes by delivering innovative and cost-effective solutions across therapeutic areas such as cardiovascular, central nervous system, and infectious diseases, among others.

What is the P/E ratio of Amneal Pharmaceuticals 2024?

The Amneal Pharmaceuticals P/E ratio is 8.31.

What is the P/S ratio of Amneal Pharmaceuticals 2024?

The Amneal Pharmaceuticals P/S ratio is 0.58.

What is the AlleAktien quality score of Amneal Pharmaceuticals?

The AlleAktien quality score for Amneal Pharmaceuticals is 5/10.

What is the revenue of Amneal Pharmaceuticals 2024?

The expected Amneal Pharmaceuticals revenue is 2.61 B USD.

How high is the profit of Amneal Pharmaceuticals 2024?

The expected Amneal Pharmaceuticals profit is 182.6 M USD.

What is the business model of Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is an internationally operating company in the pharmaceutical industry that specializes in the development, manufacturing, and marketing of generics and innovative products. The business model is based on a diversified production and sales strategy, which enables the company to be successful in different markets and product categories. The company is active in several segments, including generics, innovative products, specialty pharma, and biosimilars. In the generics segment, the company offers a variety of high-quality generic drugs for different therapeutic areas, which have the same quality and efficacy as the original products. The innovative products include innovative drugs for rare diseases and specialized therapeutic areas. In the specialty pharma segment, the company offers a wide range of drugs for specialized therapies, which are often intended for patients with severe or rare diseases. The biosimilars segment focuses on the development and marketing of biosimilars for various therapy areas, such as oncology. Amneal Pharmaceuticals Inc also offers over-the-counter drugs, dietary supplements, and cosmetics. The company has successfully launched a variety of products in these categories to meet the consumers' needs for self-care products and a healthy lifestyle. Another important aspect of Amneal Pharmaceuticals Inc's business model is the targeted expansion of the company through strategic acquisitions and partnerships. In the past, the company has already made some successful acquisitions of competitors to expand its product portfolio and increase sales. The company places particular emphasis on quality assurance and sustainable business practices. Amneal Pharmaceuticals Inc pursues a comprehensive quality management system that meets the highest requirements and standards. Sustainability also plays an important role in the company's business model. Amneal Pharmaceuticals Inc aims to develop environmentally friendly processes and products to contribute to the protection of the environment. In summary, the business model of Amneal Pharmaceuticals Inc is based on a broad range of products, diversified sales strategies, and targeted expansion and acquisition strategies. The consistent adherence to the highest quality and sustainability standards, as well as the focus on specialty therapies and innovative products, have made the company an important player in the pharmaceutical industry. Only the first and the last sentence are to be written in the answer field.

What is the Amneal Pharmaceuticals dividend?

Amneal Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Amneal Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Amneal Pharmaceuticals or the company does not pay out a dividend.

What is the Amneal Pharmaceuticals ISIN?

The ISIN of Amneal Pharmaceuticals is US03168L1052.

What is the Amneal Pharmaceuticals WKN?

The WKN of Amneal Pharmaceuticals is A2JLMD.

What is the Amneal Pharmaceuticals ticker?

The ticker of Amneal Pharmaceuticals is AMRX.

How much dividend does Amneal Pharmaceuticals pay?

Over the past 12 months, Amneal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amneal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amneal Pharmaceuticals?

The current dividend yield of Amneal Pharmaceuticals is .

When does Amneal Pharmaceuticals pay dividends?

Amneal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amneal Pharmaceuticals?

Amneal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amneal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amneal Pharmaceuticals located?

Amneal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amneal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amneal Pharmaceuticals from 9/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did Amneal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/16/2024.

What was the dividend of Amneal Pharmaceuticals in the year 2023?

In the year 2023, Amneal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amneal Pharmaceuticals pay out the dividend?

The dividends of Amneal Pharmaceuticals are distributed in USD.

All fundamentals about Amneal Pharmaceuticals

Our stock analysis for Amneal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amneal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.